CD274 and head and neck squamous cell carcinoma: Although blockade of the PD-1/PD-L1 pathway using monoclonal antibodies is a novel therapeutic strategy for treating patients with recurrent HNSCC [27], the association between PD-L1 expression and the prognosis of patients with HNSCC has not been well described.